Center for Neurologic Study
The Center for Neurologic Study is a nonprofit organization specializing in translational medicine for neurological disorders, with notable achievements including the approval of Qalsody/Tofersen for ALS treatment and pioneering research in neurotherapeutics. The organization focuses on drug discovery, development, and research to address significant unmet medical needs in neurodegenerative diseases.
Industries
Nr. of Employees
small (1-50)
Center for Neurologic Study
Patents
Products
Clinical lability assessment scale (clinical outcome measure)
A clinician-validated scale for assessing emotional lability/pseudobulbar affect; has undergone translation and validation work to support cross-cultural use.
Clinical lability assessment scale (clinical outcome measure)
A clinician-validated scale for assessing emotional lability/pseudobulbar affect; has undergone translation and validation work to support cross-cultural use.
Services
Provide equity seed investments, strategic advice, mentorship, and network access to early-stage biotechnology projects focused on neurodegenerative and CNS disorders.
Design, synthesis, and preclinical characterization of candidate therapeutic molecules with emphasis on CNS delivery, ADME assessment, and early 'druggability' evaluation.
Conduct biomarker discovery, targeted lipid profiling, immunohistochemistry, and immunofluorescence studies to investigate disease mechanisms and identify diagnostic or prognostic markers.
Provide equity seed investments, strategic advice, mentorship, and network access to early-stage biotechnology projects focused on neurodegenerative and CNS disorders.
Design, synthesis, and preclinical characterization of candidate therapeutic molecules with emphasis on CNS delivery, ADME assessment, and early 'druggability' evaluation.
Conduct biomarker discovery, targeted lipid profiling, immunohistochemistry, and immunofluorescence studies to investigate disease mechanisms and identify diagnostic or prognostic markers.
Expertise Areas
- CNS drug discovery and translational medicine
- Clinical trial design and execution for neurological disorders
- Biomarker discovery and assay development
- Medicinal chemistry and ADME/BBB evaluation
Key Technologies
- Antisense oligonucleotides
- siRNA therapeutics
- Monoclonal antibodies and biologics
- Nanoparticle-based formulations
News & Updates
Pathogenesis of Alzheimer's disease: Involvement of the choroid plexus
A publication in Alzheimer's & Dementia on the involvement of the choroid plexus in Alzheimer's disease.
Self-Replicating Proteins in ALS & CNS Disorders
Research highlighting the role of self-replicating proteins in sporadic ALS and related disorders.
June 2024 - Qalsody (Tofersen) Approved For Use in Europe
Announcement of the approval of Qalsody/Tofersen in Europe, conceived by CNS Director Dr. Smith.
Chinese Translation and Validation of the Center for Neurologic Study Lability Scale
Publication of the Chinese translation and validation of a scale for measuring lability in neurological disorders.
Identification of Sporadic ALS and Related Diseases
A publication in Nature Neurology Reviews highlighting research on sporadic ALS.
Approval of Qalsody/Tofersen for ALS
Achieved a significant milestone in ALS treatment with the FDA approval of Qalsody/Tofersen.
Pathogenesis of Alzheimer's disease: Involvement of the choroid plexus
A publication in Alzheimer's & Dementia on the involvement of the choroid plexus in Alzheimer's disease.
Self-Replicating Proteins in ALS & CNS Disorders
Research highlighting the role of self-replicating proteins in sporadic ALS and related disorders.
June 2024 - Qalsody (Tofersen) Approved For Use in Europe
Announcement of the approval of Qalsody/Tofersen in Europe, conceived by CNS Director Dr. Smith.
Chinese Translation and Validation of the Center for Neurologic Study Lability Scale
Publication of the Chinese translation and validation of a scale for measuring lability in neurological disorders.
Identification of Sporadic ALS and Related Diseases
A publication in Nature Neurology Reviews highlighting research on sporadic ALS.
Approval of Qalsody/Tofersen for ALS
Achieved a significant milestone in ALS treatment with the FDA approval of Qalsody/Tofersen.